Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment

Dual block HER2 assessment can effectively increase the HER2 positive rate in resected specimens of gastric cancer (GC). The aim of this study is to explore whether GC patients with extra gained HER2 positivity by dual block assessment can benefit from trastuzumab therapy. Twenty-eight GC patients r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Chen, Liu, Yalan, Jiang, Dongxian, Ge, Xiaowen, Huang, Jie, Su, Jieakesu, Zhang, Xue, Lu, Shaohua, Ji, Yuan, Hou, Jun, Liu, Tianshu, Hou, Yingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914406/
https://www.ncbi.nlm.nih.gov/pubmed/31739285
http://dx.doi.org/10.18632/aging.102415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6914406/
https://www.ncbi.nlm.nih.gov/pubmed/31739285
http://dx.doi.org/10.18632/aging.102415

Ejemplares similares